Differences in outcomes for patients with bacteremia due to vancomycin- resistant Enterococcus faecium or vancomycin-susceptible E. faecium

Clinical Infectious Diseases

Volumn 22, Issue 4, 1996, Pages 663-670

  Linden, Peter K ^a   Pasculle, Anthony W ^a   Manez, Rafael ^a   Kramer, David J ^a   Fung, John J ^a   Pinna, Anthony D ^a   Kusne, Shimon ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; DALFOPRISTIN; NOVOBIOCIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL EXAMINATION; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; SURGICAL DRAINAGE; SURVIVAL; TREATMENT OUTCOME;

EID: 0029816851     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.4.663     Document Type: Article

References (44)

1. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
2. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
3. The Centers for Disease Control and Prevention. Preventing the spread of vancomycin-resistance - report from the hospital infection control practices advisory committee. Comment period and public meeting. Federal Register 1994;59:25758-63.
4. Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-9.
5. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
6. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.
7. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin Infect Dis 1993;16:750-5.
8. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
9. Cohen ML. Epidemiology of drug resistance: implications for a post-antibiotic era. Science 1992;257:1050-5.
10. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 1989;27:194-203.
11. Shlaes DM, Etter L, Gutmann L. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother 1991; 35:776-9.
12. Fraimow HS, Venuti E. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1992;36:1563-6.
13. Landman D, Mobarakai NK, Quale JM. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin and gentamicin. Antimicrob Agents Chemother 1993;37:1904-8.
14. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC Jr. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:598-601.
15. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/ dalfopristin [letter]. Lancet 1994;344:1025-6.
16. Linden P, Pasculle AW, Riddler S, et al. Quinupristin/dalfopristin for the treatment of serious infection due to high level vancomycin-resistant Enterococcus faecium [abstract no M-68]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994.
17. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
18. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:72S-75S.
19. Landry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 1989;17:323-9.
20. Green M, Binczewski B, Pasculle AW, et al. Constitutively vancomycin-resistant Enterococcus faecium resistant to Synergistic beta-lactam combinations. Antimicrob Agents Chemother 1993;37:1238-42.
21. Facklam RR, Sahm DF. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995:308-14.
22. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 3rd ed. NCCLS document M7-A3. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
23. Swenson JM, Ferraro MJ, Sahm DF, Tenover FC, the Working Group on Enterococci. Recommended guidelines for detection of high-level aminoglycoside resistance in enterococci [abstract no 263]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). American Society for Microbiology, 1993.
24. Yu VL. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med 1981; 94:784-5.
25. Dougherty SH, Flohr AB, Simmons RL. 'Breakthrough' enterococcal septicemia in surgical patients. 19 cases and a review of the literature. Arch Surg 1983;118:232-8.
26. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988;67: 248-69.
27. Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia: analysis of 75 episodes. Rev Infect Dis 1989;11:74-85.
28. Shlaes DM, Levy J, Wolinsky E. Enterococcal bacteremia without endocarditis. Arch Intern Med 1981;141:578-81.
29. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991;13:600-5.
30. Barrall DT, Kenney PR, Slotman GJ, Burchard KW. Enterococcal bacteremia in surgical patients. Arch Surg 1985;120:57-63.
31. Bryan CS, Reynolds KL, Brown JJ. Mortality associated with enterococcal bacteremia. Surg Gynecol Obstet 1985;160:557-661.
32. Garrison RN, Fry DE, Berberich S, Polk HC Jr. Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg 1982;196: 43-7.
33. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995;20:296-301.
34. Moellering RC Jr. The Garrod Lecture. The Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1-12.
35. Tsao MMP, Katz D. Central venous catheter-induced endocarditis: human correlate of the animal experimental model of endocarditis. Rev Infect Dis 1984;6:783-90.
36. Rowley KM, Clubb KS, Walker-Smith GJ, Cabin HS. Right-sided infective endocarditis as a consequence of flow-directed pulmonary-artery catheterization: a clinicopathological study of 55 autopsied patients. N Engl J Med 1984;311:1152-6.
37. Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. Clin Microbiol Rev 1994;7:462-78.
38. Nichols RL, Muzik AC. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992;15:72-6.
39. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.
40. Moellering RC Jr. Treatment of enterococcal endocarditis. In: Sande MA, Kaye D, Root RK, eds. Endocarditis. New York: Churchill Livingstone, 1984:113-33.
41. Bayer AS, Seidel JS, Yoshikawa TT, Anthony BF, Guze LB. Group D enterococcal meningitis. Clinical and therapeutic considerations with report of three cases and review of the literature. Arch Intern Med 1976;136:883-6.
42. Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991;164:1212-5.
43. Huycke MM, Spiegel CA, Gilmore MS. Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1991;35:1626-34.
44. DeCelis G, Pallares R, Gudiol F, Ariza J, Nogues FF. Role of appropriate antimicrobial therapy in outcome of enterococcal bacteremia. Am J Med 1987;82:1283-4.